Medicamen Biotech Ltd Stock Analysis

BSE: 531146 | NSE: MEDICAMEQ | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 08-Feb-2023 18:01
731.20 1.25 (0.17%)

DeciZen - Make an Informed Decision on Medicamen Biotech

Overall Rating

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

Medicamen Biotech Price Chart

P/E Ratio ( SA) :
67.38
Market Cap :
925.1 Cr.
52-wk low :
558.8
52-wk high :
1,219
Bole Toh?

1. Is Medicamen Biotech Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Medicamen Biotech Ltd is a below average quality company.

2. Is Medicamen Biotech Ltd undervalued or overvalued?

The key valuation ratios of Medicamen Biotech Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Medicamen Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Medicamen Biotech Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Medicamen Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Medicamen Biotech Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % -7.4%8.5%7.8%6.9%18.2%16.4%12%10.3%9.2%9.3%-
Value Creation Index -1.5-0.4-0.5-0.50.30.2-0.1-0.3-0.3-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 6473.377.867.382.5112123117110115122
YoY Gr. Rt. %-14.5%6.2%-13.5%22.6%35.2%10%-4.3%-6.1%4.8%-
Adj EPS -6-0.1-00.14.87.78.89.21011.410.9
YoY Gr. Rt. %-NANANA4650%62.5%14.1%4.8%7.8%14.3%-
BVPS (₹) 18.518.317.817.924.763.773.798.6104.5114.8141.8
Adj Net Profit -5.1-0.100.15910.311.312.213.914
Cash Flow from Ops. -1.65.1-3.36.23.6-5.54.311.7134.8-
Debt/CF from Ops. -10.73-6.33.34.9-2.72.711.55.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.8%7%-2%4.8%
Adj EPS NA19.1%8.9%14.3%
BVPS 22.53615.99.9
Share Price 50.5% 1.2% 29.4% -7.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % -28.4-0.5-0.20.622.417.812.810.89.59.88.5
Op. Profit Mgn % -0.47.16.58.214.115.114.315.518.220.918.7
Net Profit Mgn % -8-0.1-0.10.26.18.18.49.6111211.3
Debt to Equity 1.111.21.10.70.20.10.10.20.20
Working Cap Days 233198201230197196235287310332400
Cash Conv. Cycle 52384242376474716688216

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 8.50%

Sales growth has been subdued in last 3 years -1.98%

Net Profit has been subdued in last 3 years 8.88%

Sales growth is not so good in last 4 quarters at 8.58%

Latest Financials - Medicamen Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) 10.9 10.8
TTM Sales (₹ Cr.) 122 122
BVPS (₹.) 141.8 140.8
Reserves (₹ Cr.) 175 173
P/BV 5.16 5.19
PE 67.38 67.36
From the Market
52 Week Low / High (₹) 558.80 / 1219.00
All Time Low / High (₹) 2.25 / 1219.00
Market Cap (₹ Cr.) 925
Equity (₹ Cr.) 12.7
Face Value (₹) 10
Industry PE 33.7

Management X-Ray of Medicamen Biotech :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Medicamen Biotech

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Medicamen Biotech Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Medicamen Biotech on 08-Feb-2023 18:01 is : 731.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 08-Feb-2023 18:01 the market cap of Medicamen Biotech stood at ₹ 925.0.
The latest PE ratio of Medicamen Biotech as of 08-Feb-2023 18:01 is 67.38.
The latest PB ratio of Medicamen Biotech as of 08-Feb-2023 18:01 is 5.16
The 52-week high of Medicamen Biotech is ₹ 1,219 and the 52-week low is ₹ 558.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Medicamen Biotech is ₹ 122.0 ( Cr.) .

About Medicamen Biotech Ltd

Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Medicamen Biotech started its operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted Mr. B.K. Gupta - Managing Director of the company to go for own manufacturing facilities. Thus in the later part of 1994 a land of 2,10,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured.

In 1995 Medicamen Biotech Limited was enlisted in Bombay Stock Exchange and public issue was oversubscribed by more than 11 times. Within a span of 10 years Medicamen Biotech Limited is now among top 50 Indian export company.

In the year 2005 keeping the pace with the ever increasing demand and fulfilling the commitment, a second unit was installed in the Tax free zone at Haridwar in the state of Uttarakhand .The Unit II is fully operational from April 2007 with ultra modern manufacturing facilities.

Product range of the company includes:

The company is the Manufacturer and supplier of Comprehensive range of products:

  • Tablets
  • Capsules
  • Liquid Syrup
  • Dry Syrup (Beta Lactum and Non Beta Lactum)
  • Ointment
  • ORS

Achievements/ recognition:

The company is the receipents of the following certificates & awards:

  • WHO-GMP
  • ISO 9001: 2000
  • Star Export House
  • Certificate Of Merit
  • “Niryat Shree” for the four consecutive years from 2002 to 2005 from Government of India
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now